Currently, there are 224.71M common shares owned by the public and among those 214.59M shares have been available to trade.
The company’s stock has a 5-day price change of -24.62% and -75.06% over the past three months. SGMO shares are trading -35.71% year to date (YTD), with the 12-month market performance up to 4.98% higher. It has a 12-month low price of $0.30 and touched a high of $3.18 over the same period. SGMO has an average intraday trading volume of 5.90 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -27.03%, -36.55%, and -43.68% respectively.
Institutional ownership of Sangamo Therapeutics Inc (NASDAQ: SGMO) shares accounts for 27.61% of the company’s 224.71M shares outstanding.
It has a market capitalization of $147.36M and a beta (3y monthly) value of 1.49. The earnings-per-share (ttm) stands at -$0.52. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.50% over the week and 11.02% over the month.
Analysts forecast that Sangamo Therapeutics Inc (SGMO) will achieve an EPS of -0.13 for the current quarter, -0.14 for the next quarter and -0.35 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.13 while analysts give the company a high EPS estimate of -0.13. Comparatively, EPS for the current quarter was -0.25 a year ago. Earnings per share for the fiscal year are expected to increase by 48.40%, and -33.33% over the next financial year.
Looking at the support for the SGMO, a number of firms have released research notes about the stock. Truist stated their Buy rating for the stock in a research note on December 13, 2024, with the firm’s price target at $7. H.C. Wainwright coverage for the Sangamo Therapeutics Inc (SGMO) stock in a research note released on December 10, 2024 offered a Buy rating with a price target of $10. RBC Capital Mkts was of a view on November 03, 2023 that the stock is Sector Perform, while BofA Securities gave the stock Underperform rating on April 28, 2023, issuing a price target of $5- $1.50. Wedbush on their part issued Outperform rating on February 27, 2023.
